Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan and Adebrelimab in Triple Negative Breast Cancer
NCT07679360Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan, adebrelimab in triple-negative breast cancer (TNBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Sep 2026; status: recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07679360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679360.